- Home
- FOCL vs ANTX Comparison
FOCL vs ANTX Comparison
Compare FOCL & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOCL | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | France | United States |
| Employees | 289 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 172.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | FOCL | ANTX |
|---|---|---|
| Price | $6.13 | $4.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 44.3K | ★ 204.0K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.76 | $1.00 |
| 52 Week High | $6.18 | $6.91 |
Technical Indicators
Market Signals| Indicator | FOCL | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 88.29 | 56.12 |
| Support Level | $5.30 | $3.91 |
| Resistance Level | N/A | $5.15 |
| Average True Range (ATR) | 0.19 | 0.35 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 93.75 | 71.30 |
Price Performance
Historical ComparisonAbout FOCL EDAP TMS S.A. American Depositary Shares
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.